Tuesday, 17 November 2026 Every SEC filing alert, by company
ALFA USA Filings Every alert, straight from SEC EDGAR
News

DataMeds AI, Inc.

NASDAQ: MEDS · Trade & Services · 10 alerts · CIK 2030763

Share price
$0.6421Close, Nov 16
Market cap
$3.68M
Shares outstanding
5.72MLatest SEC cover page
Sector
Trade & Services
Industry
Wholesale-Drugs, Proprietaries & Druggists' SundriesSIC 5122

Today's reference numbers: shares from the company's latest SEC cover page, price from the latest market close. Not a valuation or a recommendation. All DataMeds AI, Inc. filings on SEC EDGAR ↗

6:14 AM ET 8-K
Capital Raise

DataMeds AI Capital Raise

DataMEDS AI, Inc. entered into an at-the-market (ATM) sales agreement with Dawson James Securities, Inc. to establish an offering program for its common stock. The company may sell shares from time to time at prevailing market prices, though it is not obligated to make any sales. The Sales Agent will receive a fixed commission of 3.0% of the gross proceeds from any shares sold.

Counterparty
Dawson James Securities, Inc.
5:13 PM ET 10-Q
Financial Results

DataMeds AI Q3 2026 Results: Turns Profitable, Net Income $10.6M

DataMeds AI, Inc. (formerly Wellgistics Health, Inc.) reported a net income of $10.5 million for the quarter ended September 30, 2026, primarily driven by a $19.1 million gain on debt extinguishment. However, the company experienced a significant decline in nine-month revenues from $21.7 million in 2025 to $6.0 million in 2026, resulting in a year-to-date net loss of $15.6 million.

Key figure
Net income $10.6M
4:16 PM ET 8-K
Financial Results

DataMeds AI Financial Results

DataMEDS AI reported Q3 2026 revenue of $2.7 million, representing 50% sequential growth driven by its Corexa Pharmacy drug dispensing business. The company achieved a net profit of $2.72 per share and regained full compliance with Nasdaq listing standards during the period. Key strategic developments included the launch of the Health Lives Here mobile app and the acquisition of the Helomics cancer diagnostics laboratory.

Term
Q3 2026

“Corexa Pharmacy drove a 50% sequential increase in revenue this quarter with continued growth expected for the fourth quarter based upon the steps we have taken to add additional revenue streams of medical foods and diagnostic lab tests related to patients to whom we dispense prescriptions.”

Gerald Commissiong, Interim Co-CEO of DataMEDS
6:08 AM ET 8-K
Deal Termination

DataMeds AI Deal Termination with EOS Technology Holdings, Inc.

DataMEDS AI, Inc. has terminated its Second Amended and Restated Letter of Intent (LOI) with multiple parties including EOS Technology Holdings, Scilex, and Datavault AI. The LOI contemplated the acquisition of intellectual property assets and a controlling interest in Tollo Health in exchange for common stock, but was cancelled due to market conditions. The company stated that no shares will be issued and no fees are owed as a result of the termination.

Counterparty
EOS Technology Holdings, Inc.
5:01 PM ET 8-K
M&A Deal

DataMeds AI M&A Deal with EOS Technology Holdings, Inc.

DataMEDS AI entered into a second amended and restated non-binding letter of intent to acquire intellectual property assets from EOS and Scilex Holding Company, and a controlling interest in Tollo Health (d/b/a Health Lives Here). The transaction involves an exchange of membership interests and the issuance of common stock that will result in the counterparties owning approximately 89.5% of the company's common stock on a fully diluted basis.

Counterparty
EOS Technology Holdings, Inc.
9:24 AM ET 8-K
Nasdaq/NYSE Compliance Notice

DataMeds AI Nasdaq/NYSE Compliance Notice

DataMeds AI, Inc. received formal notification from Nasdaq on October 19, 2026, confirming that the company has regained compliance with the $2.5 million minimum stockholders' equity requirement for continued listing. The company had previously been in deficiency since April 2026 and had also recently regained compliance with the minimum bid-price requirement in June 2026.

Counterparty
Nasdaq
5:15 PM ET 8-K
Licensing Deal

DataMeds AI Licensing Deal with REBOOT Health AI, Inc. Worth $2M

DataMeds AI, Inc. entered into an exclusive intellectual property license agreement with REBOOT Health AI to use its AI platform for DataMeds' GLP-1 weight management business. As consideration, DataMeds will issue 666,667 shares of common stock with a guaranteed minimum value of $2 million after 180 days, plus a revenue-sharing arrangement. The company also disclosed it remains below Nasdaq's minimum stockholders' equity requirement for continued listing.

Value
$2M
Counterparty
REBOOT Health AI, Inc.
Term
perpetuity
5:27 PM ET 8-K
Court & Legal Update

DataMeds AI Court & Legal Update

DataMeds AI entered into a settlement agreement with Brian Norton and other parties to resolve litigation in Florida and Delaware related to a 2023 Membership Interest Purchase Agreement. The company paid $450,000 to settle all claims and repurchase 364,099 shares, resulting in the extinguishment of approximately $19 million in balance sheet liabilities.

Counterparty
Brian Norton
5:23 PM ET 8-K
Court & Legal Update

DataMeds AI Court & Legal Update

DataMeds AI entered into a settlement agreement with Brian Norton and other settling parties to resolve litigation in Florida and Delaware concerning a 2023 Membership Interest Purchase Agreement. The company paid $450,000 to settle all claims and repurchase 364,099 shares of common stock, a move expected to extinguish approximately $19 million in liabilities from its balance sheet.

Counterparty
Brian Norton

Get Alerts

Get ALFA Finder alerts first

Real-time SEC filing alerts for US stocks are launching soon. Leave your details and we'll tell you the moment they go live.